Israel has quietly built one of the most coveted repositories of structured medical information in the world, and a growing roster of multinational corporations — from pharmaceutical giant Pfizer to artificial intelligence company OpenAI — are moving aggressively to tap it. As the Calcalist report details, the country’s universal healthcare system and its decades of digitized patient records are reshaping how global technology and life-sciences companies approach drug discovery, clinical research, and AI model training. For a country of roughly nine million people, the scale of data access on offer is disproportionately significant, and the commercial stakes are rising fast.
Israel’s four major health maintenance organizations — known locally as kupot holim — collectively cover nearly the entire population and have been digitizing patient records since the early 1990s. That gives researchers access to longitudinal health data spanning more than three decades, covering millions of patients across diverse demographic cohorts. The depth and continuity of those records is rare globally, and increasingly difficult to replicate elsewhere given tightening data privacy regulations in Europe and complex fragmentation in the United States health system. The intersection of oncology research and large-scale data infrastructure is precisely the kind of environment attracting serious capital.
Why the Data Is Structurally Different
What distinguishes Israeli health data from other national registries is its combination of completeness, structure, and clinical depth. Because HMO membership is mandatory and largely stable over a citizen’s lifetime, records track individuals through chronic illness, treatment cycles, pharmaceutical interventions, and long-term outcomes in a continuous, linked format. This continuity is precisely what machine learning systems require to identify patterns across disease progression and treatment efficacy — tasks that demand not just volume but consistency of data collection over time.
Maccabi Healthcare Services, one of the largest HMOs with approximately 2.7 million members, has been among the most active in formalizing partnerships with international technology companies. Its MaccabiTech subsidiary has structured data-sharing arrangements aimed specifically at enabling AI-driven research. Clalit Health Services, covering around 4.7 million members — more than half the Israeli population — has similarly entered collaborations with global pharmaceutical firms for drug development studies. The model being established is one of structured, governed access rather than outright data transfer, preserving legal compliance while enabling commercial partnerships.
Commercial Momentum and Strategic Implications
The commercial activity accelerating around Israeli health data reflects a broader global race among technology and pharmaceutical firms to secure proprietary training sets for next-generation AI systems. OpenAI’s interest in healthcare data, reported as part of its broader push into applied AI verticals, signals that the competition for structured medical records is no longer limited to traditional pharmaceutical players. The entry of large-scale AI developers into this space is pushing valuations and negotiating leverage for Israeli health institutions meaningfully higher.
Pfizer’s engagement reflects the pharmaceutical industry’s strategic calculation that AI-accelerated drug discovery could compress development timelines by years, reducing the roughly one-billion-dollar average cost associated with bringing a new compound to market. Access to real-world evidence data — as opposed to controlled trial data alone — is central to that ambition. Israeli datasets, with their multi-decade patient histories, provide exactly that kind of real-world longitudinal signal. Regulatory alignment also plays a role: Israel’s Health Ministry has moved to establish frameworks governing international data use, creating a degree of legal predictability that reduces partnership friction for foreign corporations.
The trend carries implications beyond individual commercial deals. As the market for proprietary health data matures, institutions that have invested early in data governance infrastructure are emerging as durable strategic assets. Israel’s HMOs, long viewed primarily as domestic healthcare providers, are effectively repositioning as data infrastructure companies with global relevance. That shift is drawing comparisons to the way semiconductor design expertise or cybersecurity capabilities previously elevated Israeli technology exports, and it raises substantive questions about how the financial value generated from citizen health records should ultimately be distributed. For now, the partnerships are multiplying, and the AI restructuring sweeping global industry is only intensifying demand for the kind of high-quality, structured data Israel has spent three decades accumulating.